Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189623
DOI: 10.1016/j.bbcan.2026.189623 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Joanna Pastwińska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, 90-364 Lodz, Poland. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Interleukin-17, Receptors, Interleukin-17. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instytut Biologii Medycznej Polskiej Akademii Nauk, National Science Centre Poland.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI)-based combinations have reshaped systemic therapy for unresectable hepatocellular carcinoma (HCC), yet durable responses remain limited, underscoring the need for mechanism-driven partners that reprogram the cirrhosis-conditioned tumor microenvironment. Here, we synthesize evidence supporting IL-17 family signaling as such a tractable axis and emphasize three translational takeaways. First, "IL-17 blockade" is not a single intervention: canonical IL-17A/F signaling through IL-17RA/RC differs from non-canonical nodes, including IL-17C signaling via IL-17RA/IL-17RE and the dual-ligand IL-17RB node (IL-25 versus IL-17B), which can yield context-dependent-and potentially opposing-effects. Second, HCC-focused models implicate an IL-17A-STAT3-PD-L1 immune-evasion circuit and show that IL-17A neutralization can enhance the activity of PD-1/PD-L1 blockade, positioning IL-17A/F inhibition primarily as an ICI-sensitizing strategy. Third, we argue that clinical translation should prioritize biomarker-guided, etiology-aware early-phase studies with on-treatment pharmacodynamic readouts, rather than unselected monotherapy, while explicitly accounting for infection and gut-barrier risks in cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, 90-364 Lodz, Poland.
- Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, 90-364 Lodz, Poland. Electronic address: mratajewski@cbm.pan.pl.
Förderung
- Instytut Biologii Medycznej Polskiej Akademii Nauk
- National Science Centre Poland
Zitieren
APA
Pastwińska, J., Karwaciak, I., Karaś, K., Sałkowska, A., & Ratajewski, M. (2026). Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189623. https://doi.org/10.1016/j.bbcan.2026.189623
Vancouver
Pastwińska J, Karwaciak I, Karaś K, Sałkowska A, Ratajewski M. Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189623. doi:10.1016/j.bbcan.2026.189623
BibTeX
@article{Pastwiska2026,
author = {Pastwińska, Joanna and Karwaciak, Iwona and Karaś, Kaja and Sałkowska, Anna and Ratajewski, Marcin},
title = {Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189623},
doi = {10.1016/j.bbcan.2026.189623}
}
EUVIMED